Vanguard Group Inc Bio Atla, Inc. Transaction History
Vanguard Group Inc
- $5.12 Trillion
- Q2 2024
A detailed history of Vanguard Group Inc transactions in Bio Atla, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,885,252 shares of BCAB stock, worth $3.88 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,885,252
Previous 2,099,037
10.18%
Holding current value
$3.88 Million
Previous $7.22 Million
64.24%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding BCAB
# of Institutions
83Shares Held
22.4MCall Options Held
10.7KPut Options Held
7.4K-
Soleus Capital Management, L.P. Greenwich, CT3.9MShares$8.04 Million0.54% of portfolio
-
Morgan Stanley New York, NY1.85MShares$3.82 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.65MShares$3.4 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA1.37MShares$2.83 Million0.23% of portfolio
-
Deutsche Bank Ag\ Frankfurt Am Main, 2M1.2MShares$2.46 Million0.0% of portfolio
About BioAtla, Inc.
- Ticker BCAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,304,100
- Market Cap $74.8M
- Description
- BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...